[Progress in the treatment of osteoporosis].
The purpose of the treatment of osteoporosis is to reduce fracture risk and maintain/improve quality of life (QOL). The criteria for initiating pharmacotherapy to prevent fragility fractures should be provided separately from the criteria for diagnosis of osteoporosis. In Japan, low bone mineral density (BMD), prevalent fracture, and age are established as fracture risk factors from available data. A meta-analysis conducted by the WHO assured that excessive drinking (2 units a day or more), current smoking, and a family history of hip fracture are fracture risk factors. Moreover, in WHO technical report 921, high levels of CTX, a bone resorption marker as well as uncarboxylated osteocalcin were cited as risk factors of hip fracture, which can be measured in medical practice in Japan. Pharmacotherapy should be initiated with the consideration of the above risk factors. Recent large scale of randomized control trial(RCT), followed by meta-analysis demonstrated that bisphosphonates such as alendronate and risedronate as well as raloxifene (selective estrogen receptor modulator) are top grade of drugs which prevent fragility fracture in osteoporotic patients. Now, it is possible to perform evidence-based medicine in daily medical practice. As for secondary osteoporosis, along with treatment of underlying diseases, treatment aimed at preventing bone loss is necessary in many cases. Accumulating evidence is available about increased fracture threshold in glucocorticoid- and diabetes mellitus-induced osteoporosis. Therefore, early treatment should be appropriate in these cases. In osteoporotic patients, atherosclerotic vascular calcification as well as abnormal lipid metabolism often coexists. Multiple vertebral fractures followed by kyphosis often causes functional disorders of the digestive and respiratory systems.
Sugimoto
Toshitsugu
T
Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan. sugimoto@med.shimane-u.ac.jp
D050197:Atherosclerosis; D015415:Biomarkers / Q000652:urine; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D024042:Collagen Type I / Q000652:urine; D004164:Diphosphonates / Q000627:therapeutic use; D050171:Dyslipidemias; D019317:Evidence-Based Medicine; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D015675:Osteocalcin / Q000652:urine; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D010455:Peptides / Q000652:urine; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin